Exclusive special offer and discount title banner vector image

GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Global RNA Interference (RNAi) Drug Delivery Market by Application (Oncology, Infectious Disease, Neurology, Cardiology, Metabolic Disorders, Ophthalmology, Urology, Other Applications) Market by Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery) by Geography

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The global RNA interference (RNAi) drug delivery market size was $66,442.85 million in 2023 and is expected to reach $406,320.39 million by 2032, growing at a CAGR of 22.24% during the forecast period. The base year considered for the study is 2023, and the estimated period is between 2024 and 2032.

The RNAi technology has emerged as a promising therapeutic approach, harnessing the body’s natural mechanism of gene silencing. RNAi drugs, also known as small interfering RNAs (siRNAs), can selectively target and degrade specific disease-causing genes, offering potential treatments for various conditions. However, delivering these therapeutic molecules presents a critical challenge due to their susceptibility to degradation and the barriers they encounter in reaching their target cells and tissues.

Consequently, to overcome these obstacles, researchers have developed various drug delivery systems for RNA therapeutics, including lipid nanoparticles, polymer-based nanocarriers, and conjugation with targeting ligands. These systems are designed to shield siRNAs from degradation, aid in their uptake by cells, and improve their specificity for targeting desired cells or tissues.

A substantial challenge in RNAi therapy is the potential for RNAi off-target effects, where the siRNAs unintentionally silence genes other than the intended target. This can lead to undesirable side effects and reduced therapeutic efficacy. In this regard, researchers are continuously working on improving the specificity and potency of RNAi therapeutics through advanced RNA interference drug delivery technology and chemical modifications.

Furthermore, RNA interference (RNAi) is a natural cellular process that selectively degrades specific messenger RNAs (mRNAs), regulating gene expression and preventing the production of corresponding proteins. RNAi delivery methods aim to use this mechanism for therapeutic purposes by introducing synthetic siRNAs into target cells or tissues. Several RNAi companies, including Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals, are actively involved in developing and commercializing RNAi therapeutics. As the field of RNAi drug delivery continues to evolve, and collaboration between academia, industry, and regulatory agencies will be crucial. This collaboration is necessary for addressing the remaining challenges and translating this promising technology into safe and effective treatments for patients.

GLOBAL-RNA-INTERFERENCE-(RNAi)-DURG-DELIVERY-MARKET SIZE

Read our latest blog on the RNA Interference (RNAi) Drug Delivery Market

GROWTH ENABLERS

Key growth enablers of the global RNA interference (RNAi) drug delivery market: 

  • Increasing demand for RNA-based therapeutics to stimulate market growth
  • Rising prevalence of chronic diseases fosters market demand
    • The increasing prevalence of chronic diseases can be attributed to factors such as an aging population and the rise in lifestyle diseases. This trend underscores the growing demand for innovative treatments, including those leveraging RNA interference technology. 
    • According to WHO statistics, the proportion of the world’s population over 60 years old is projected to almost double from 12% to 22% by 2050. This shift is a result of longer life expectancies and declining birth rates in various regions globally.
    • Additionally, it is a trend that underscores the importance of healthcare innovation, including advancements in RNA therapeutics, to meet the needs of an aging society.
  • Growing investment in RNA-based research to escalate the market growth

GROWTH RESTRAINTS

Key growth restraining factors of the global RNA interference (RNAi) drug delivery market:

  • The complexity of RNAi technology is predicted to hinder market demand
  • Regulatory challenges are expected to further complicate market growth
    • The regulatory landscape for RNAi therapeutics presents considerable challenges due to the novelty and complexity of this technology. Regulatory agencies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established rigorous standards and requirements for developing and approving RNAi-based therapies.

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global RNA Interference (RNAi) Drug Delivery Market | Top Market Trends

  • RNAi drugs have reflected effectiveness in cancer treatment by targeting genes involved in tumorigenesis, leading to antiproliferative and proapoptotic effects. However, challenges persist in drug delivery and toxicity. Despite these challenges, the substantial annual investments of over $50 billion in cancer research highlight the potential of RNAi therapies to address unmet needs in oncology.
  • The success of mRNA vaccines during the COVID-19 pandemic has heightened awareness and acceptance of RNA-based therapeutics. This has underlined the potential of RNAi drugs in treating zoonotic and other infectious diseases, with climate change and increased human-animal interactions raising the likelihood of future pandemics.
  • Venture capital and corporate funding for RNAi drugs have surged, propelled by their potential to transform the pharmaceutical industry. 

MARKET SEGMENTATION

GLOBAL-RNA-INTERFERENCE-(RNAi)-DURG-DELIVERY-MARKET-GROWTH

Need a custom report or have specific data requirements? Let us know!

Market Segmentation – Application and Technology –Market by Application:
  • Oncology
    • In 2023, the oncology segment was the largest application category in the global RNA interference (RNAi) drug delivery market.
    • RNAi has shown immense potential in the field of oncology. These drugs can target oncogenes, anti-apoptotic genes, and genes involved in angiogenesis by silencing specific genes associated with tumor growth, metastasis, and resistance to traditional therapies.
  • Infectious Disease
  • Neurology
  • Cardiology
  • Metabolic Disorders
  • Ophthalmology
  • Urology
  • Other Applications
Market by Technology:

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions: 

  • North America: The United States and Canada
    • In 2023, North America was the major region in the global RNA interference (RNAi) drug delivery market.
    • North America, particularly the United States, is a global leader in biotechnology research and development. 
    • Numerous pharmaceutical and biotech companies, along with academic institutions, are actively engaged in RNAi research, contributing to the development of novel RNAi-based therapies for various therapeutic areas.
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, Thailand, Indonesia, Vietnam, and Rest of Asia-Pacific 
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global RNA interference (RNAi) drug delivery market:

  • Alnylam Pharmaceuticals Inc
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics Inc
  • Arrowhead Pharmaceuticals Inc
  • Benitec Biopharma Inc
  • Genevant Sciences Corporation
  • Ionis Pharmaceuticals Inc
  • OliX Pharmaceuticals
  • Silence Therapeutics PLC
  • Sirnaomics Inc

Key strategies adopted by some of these companies:

  • Benitec Biopharma reported positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study in April 2024.
  • Arcturus Therapeutics and the Cystic Fibrosis Foundation extended their agreement in September 2023 to advance ARCT-032, an investigational mRNA therapeutic for treating cystic fibrosis.
  • Alnylam announced a partnership with Roche in July 2023 to co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedApplication and Technology
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Arcturus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Benitec Biopharma, Eleven Therapeutics, Genevant Sciences Corp, Ionis Pharmaceuticals Inc, Mirimus Inc, NanoDe Therapeutics Inc, OliX Pharmaceuticals, Silence Therapeutics PLC, Sirnaomics Inc, SomaGenics Inc

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON THE GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET
    5. MAJOR MARKET FINDINGS
      1. NORTH AMERICA CONSTITUTES THE HIGHEST MARKET SHARE IN TERMS OF REGION
      2. CARDIOLOGY IS THE FASTEST-GROWING RNAI DRUG DELIVERY APPLICATION
      3. NANOPARTICLE DRUG DELIVERY IS THE MAJORLY PREFERRED RNAI DRUG DELIVERY TECHNOLOGY
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING DEMAND FOR RNA-BASED THERAPEUTICS TO STIMULATE MARKET GROWTH 
      2. RISING PREVALENCE OF CHRONIC DISEASES FOSTERS MARKET DEMAND
      3. GROWING INVESTMENT IN RNA-BASED RESEARCH TO ESCALATE MARKET GROWTH
    2. KEY RESTRAINTS
      1. THE COMPLEXITY OF RNAI TECHNOLOGY IS PREDICTED TO HINDER MARKET DEMAND
      2. REGULATORY CHALLENGES ARE EXPECTED TO FURTHER COMPLICATE MARKET GROWTH
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. RNAI DRUGS HAVE APPLICATIONS IN CANCER TREATMENT
      2. EMERGING SIGNIFICANCE OF RNAI DRUGS IN RESPONDING TO GLOBAL INFECTIOUS DISEASE
      3. VENTURE FUNDING FOR RNAI DRUGS HAS INCREASED SUBSTANTIALLY 
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR GERMANY
      2. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM
      3. GROWTH PROSPECT MAPPING FOR SOUTH KOREA
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
    6. VALUE CHAIN ANALYSIS
      1. PRIMARY ACTIVITIES
        1. RESEARCH AND DEVELOPMENT (R&D)
        2. MANUFACTURING
        3. LOGISTICS AND DISTRIBUTION
        4. MARKETING AND SALES
        5. AFTER-SALES SERVICE
      2. SUPPORT ACTIVITIES
        1. PROCUREMENT
        2. TECHNOLOGY DEVELOPMENT
        3. HUMAN RESOURCE MANAGEMENT
        4. FIRM INFRASTRUCTURE
        5. REGULATORY AFFAIRS AND COMPLIANCE
    7. GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET REGULATORY FRAMEWORK
    8. KEY BUYING CRITERIA
      1. EFFICACY AND SAFETY
      2. MECHANISM OF ACTION AND TARGET SPECIFICITY
      3. DELIVERY SYSTEM AND ADMINISTRATION ROUTE
      4. COMPETITIVE ADVANTAGE AND DIFFERENTIATION
      5. REGULATORY APPROVAL AND COMPLIANCE
      6. COST AND REIMBURSEMENT
      7. INTELLECTUAL PROPERTY AND EXCLUSIVITY
      8. MANUFACTURING CAPABILITIES AND SUPPLY CHAIN
      9. COMPANY REPUTATION AND EXPERIENCE
  5. MARKET BY APPLICATION
    1. ONCOLOGY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. INFECTIOUS DISEASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. NEUROLOGY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. CARDIOLOGY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    5. METABOLIC DISORDERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    6. OPHTHALMOLOGY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    7. UROLOGY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    8. OTHER APPLICATIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY TECHNOLOGY
    1. NANOPARTICLE DRUG DELIVERY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. PULMONARY DRUG DELIVERY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. NUCLEIC ACID DRUG DELIVERY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. APTAMER DRUG DELIVERY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET DRIVERS
      3. NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET DRIVERS
      3. EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET
      5. COUNTRY ANALYSIS
        1. GERMANY
          1. GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        2. UNITED KINGDOM
          1. UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        6. BELGIUM
          1. BELGIUM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        7. POLAND
          1. POLAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET DRIVERS
      3. ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        4. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        5. SOUTH KOREA
          1. SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        7. INDONESIA
          1. INDONESIA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        8. VIETNAM
          1. VIETNAM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET DRIVERS
      3. REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET SIZE & OPPORTUNITIES
  8. COMPETITIVE LANDSCAPE
    1. KEY MARKET STRATEGIES
      1. PRODUCT LAUNCHES & DEVELOPMENTS
      2. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ALNYLAM PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      2. ARBUTUS BIOPHARMA CORP
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      3. ARCTURUS THERAPEUTICS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      4. ARROWHEAD PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      5. BENITEC BIOPHARMA
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      6. ELEVEN THERAPEUTICS
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      7. GENEVANT SCIENCES CORP
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      8. IONIS PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      9. MIRIMUS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      10. NANODE THERAPEUTICS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      11. OLIX PHARMACEUTICALS
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      12. SILENCE THERAPEUTICS PLC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      13. SIRNAOMICS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES
      14. SOMAGENICS INC
        1. COMPANY OVERVIEW
        2. PRODUCT PORTFOLIO
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – RNA INTERFERENCE (RNAI) DRUG DELIVERY

TABLE 2: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 10: GLOBAL CARDIOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL CARDIOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 12: GLOBAL METABOLIC DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL METABOLIC DISORDERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 14: GLOBAL OPHTHALMOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL OPHTHALMOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 16: GLOBAL UROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL UROLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 18: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 20: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 22: GLOBAL NANOPARTICLE DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL NANOPARTICLE DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 24: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 26: GLOBAL NUCLEIC ACID DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL NUCLEIC ACID DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 28: GLOBAL APTAMER DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL APTAMER DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 30: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY REGIONAL OUTLOOK, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY REGIONAL OUTLOOK, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 32: NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 34: KEY PLAYERS OPERATING IN NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET

TABLE 35: EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 36: EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 37: KEY PLAYERS OPERATING IN EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET

TABLE 38: ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 39: ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 40: KEY PLAYERS OPERATING IN ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET

TABLE 41: REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 42: REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 43: KEY PLAYERS OPERATING IN REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET

TABLE 44: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 45: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR GERMANY

FIGURE 4: GROWTH PROSPECT MAPPING FOR UNITED KINGDOM

FIGURE 5: GROWTH PROSPECT MAPPING FOR SOUTH KOREA

FIGURE 6: MARKET MATURITY ANALYSIS

FIGURE 7: MARKET CONCENTRATION ANALYSIS

FIGURE 8: VALUE CHAIN ANALYSIS

FIGURE 9: DRUG APPROVAL PROCESS

FIGURE 10: KEY BUYING CRITERIA

FIGURE 11: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023

FIGURE 12: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 13: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY INFECTIOUS DISEASE, 2024-2032 (IN $ MILLION)

FIGURE 14: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NEUROLOGY, 2024-2032 (IN $ MILLION)

FIGURE 15: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY CARDIOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 16: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY METABOLIC DISORDERS, 2024-2032 (IN $ MILLION)

FIGURE 17: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OPHTHALMOLOGY, 2024-2032 (IN $ MILLION)

FIGURE 18: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)

FIGURE 19: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2024-2032 (IN $ MILLION)

FIGURE 20: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2023

FIGURE 21: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NANOPARTICLE DRUG DELIVERY, 2024-2032 (IN $ MILLION)

FIGURE 22: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2032 (IN $ MILLION)

FIGURE 23: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NUCLEIC ACID DRUG DELIVERY, 2024-2032 (IN $ MILLION)

FIGURE 24: GLOBAL RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APTAMER DRUG DELIVERY, 2024-2032 (IN $ MILLION)

FIGURE 25: NORTH AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 26: UNITED STATES RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 27: CANADA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 28: EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 29: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 30: UNITED KINGDOM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 31: FRANCE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 32: ITALY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 33: SPAIN RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 34: BELGIUM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 35: POLAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 36: REST OF EUROPE RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 37: ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 38: CHINA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 39: JAPAN RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 40: INDIA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 41: AUSTRALIA & NEW ZEALAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 42: SOUTH KOREA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 43: THAILAND RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 44: INDONESIA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 45: VIETNAM RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 46: REST OF ASIA-PACIFIC RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 47: REST OF WORLD RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 48: LATIN AMERICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 49: MIDDLE EAST & AFRICA RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, 2024-2032 (IN $ MILLION)

FAQ’s

FAQs

The global RNA interference (RNAi) drug delivery market is anticipated to generate a revenue of $406.32 billion in 2032.

In 2023, the oncology application comprised the major market share and is projected to retain the position in 2032.

Pulmonary drug delivery technology is anticipated to grow at a faster rate during the forecast period.

Request Customization
Request Customization
Request free sample